Clinical trial
Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
NCT00869050 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
- Lead sponsor
- Columbia University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2005
- Completion date
- October 31, 2014
- Enrollment
- 41 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.